A Changing Landscape: The Future of Treatment for Acute Myeloid Leukemia
Advances in treatment options for acute myeloid leukemia may replace currently accepted induction regimens as the standard of care.
All articles by John Schieszer, MA
Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Current Standing and Future Directions of CAR T Therapy for Chronic Lymphocytic Leukemia
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
Better Guidelines for Diagnosing Pulmonary Embolism During Pregnancy Needed
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Guideline for Classifying Emetogenicity of Chemotherapy Agents in Pediatric Patients
Researchers classified 49 single-agent and 13 multiple-agent chemotherapy regimens by severity of emetogenicity.
Results From a Phase 2 Study Evaluating Ofatumumab for Advanced-Stage Follicular Lymphoma
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Influence of Cytogenetics on Outcomes in Relapsed Multiple Myeloma
Researchers were able to gain a better understanding of the clonal genetic landscape of relapsed multiple myeloma following autologous stem cell transplantation.
Updated Guidelines for Vaccination of Hematopoietic Stem Cell Transplant Recipients
The European Conference on Infections in Leukaemia conducted a thorough literature review to develop guidelines for safely vaccinating HSCT recipients.
Early Initiation of Hydroxyurea May Be Safe in Infants With Sickle Cell Disease
Infants with sickle cell disease who started hydroxyurea before 12 months of age had better long-term outcomes.
Long-Term Outcome Profile in Patients With Acquired Hemophilia A
Underlying lymphoproliferative syndromes, male gender, and older age may be predictive of relapse in patients with acquired hemophilia A.
Next post in Bleeding Disorders
